Pfizer

News

Bayer plans filings for prostate cancer drug darolutamide

Bayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped prevent the disease from spreading, in a niche where Pfizer and J

News

Pfizer’s CNS exit takes the form of a biotech spinout

Pfizer’s plans to duck out of central nervous system R&D have come to fruition, with the creation of spinout biotech Cerevel Therapeutics.

News

First line kidney cancer could get crowded as Merck KGaA/Pfi...

Competition in first line kidney cancer is heating up after Germany’s Merck KGaA and Pfizer briefed the ESMO conference with detailed results of their combination of the Bavencio immunother

News

Pfizer announces worldwide job cuts as part of restructure

Pfizer is planning thousands of jobs cuts worldwide as part of a round of cost-cutting as incoming CEO Albert Bourla prepares to take the helm.

News

Pfizer's Talzenna PARP breast cancer drug approved in US

The US drug regulator has approved Pfizer’s breast cancer medicine Talzenna (talazoparib) for patients with a certain mutation.

Views & Analysis

Digital health round-up: Pfizer appoints chief digital offic...

Pfizer has appointed a chief digital officer because of the growing importance of digital technology in its R&D and business process, as part of a boardroom shake-up.

Bayer plans filings for prostate cancer drug darolutamide

Pfizer’s CNS exit takes the form of a biotech spinout

First line kidney cancer could get crowded as Merck KGaA/Pfi...

Pfizer announces worldwide job cuts as part of restructure

Pfizer's Talzenna PARP breast cancer drug approved in US

Digital health round-up: Pfizer appoints chief digital offic...

AI-enabled pharmacovigilance, with Updesh Dosanjh

Discover a new era of healthcare panel engagement: Grounded ...

Pfizer

Editor's Picks